Short-acting calcium antagonists may increase coronary artery morbidity, mortality, and non-cardiovascular complications in hypertensive patients. We assessed whether this association was also true for long-acting calcium antagonists. We did a case-control study, which was nested within a systematic hypertension control programme for a prospective cohort of 4350 people (first seen 1981-94). Cases (n = 189) were hypertensive patients who had had a first cardiovascular event, including all cardiovascular deaths and hospitalisations, between 1989 and 1995. Controls (n = 189) were individually matched to cases for sex, ethnic origin, age, type of previous antihypertensive treatment, year of entry into the study, and length of follow-up. We collected data on any prescribed drug regimen that was being taken on the event data for cases and on the same date for matched controls. Calcium antagonists were classified by duration of action. Compared with those on beta-blocker monotherapy, patients on long-acting calcium antagonists (n = 136) had no increased risk of a cardiovascular event (adjusted odds ratio 0.76 [95% CI 0.41-1.43]), whereas patients on short-acting calcium antagonists (n = 27) were at significantly greater risk (adjusted...Continue Reading
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group
The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?
Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure
First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina)
Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2
Prescribing pattern of antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies
Randomised comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture
Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure
Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats
Antiischemic therapy in patients with coronary heart disease living in long-term care. Systematic Assessment of Geriatric Drug Use by Epidemiology (SAGE) Group
Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists
Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats
Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study
Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients
The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats
New approach for measurement of sympathetic nervous abnormality in conscious, spontaneously hypertensive rats
Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction
The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction
The calcium-channel blocker controversy: historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology 'hot topic'
Trends in prescribing antihypertensive drugs in the Gruppo Italiano di Farmacovigilanza nell'Anziano 1988-1997
Determinants of self-measured pulse rate profile in medicated hypertensives: the Jichi Morning Surge-1 (JMS-1) study
Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: a comparison of three drugs
Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses' Health Study
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
What constitutes success? The relative priority of service users' and clinicians' views of mental health services
Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition
Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients
Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan
L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB
Calcium antagonists for secondary prevention of myocardial infarction: is there a need to shift from short-acting to long-acting types?
Antihypertensive Agents: Mechanisms of Action
Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.
Cardiovascular Disease Pathophysiology
Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.
Antianginal Drugs: Mechanisms of Action
Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.